The United States and India sign a trade deal that lowers tariffs and changes oil purchases

Coverage is extensive (282 titles, 52 publishers) and strongly focused on the core economic and policy event (72% Economy domain, 55% Policy Change action), but shows limited representation of protest perspectives (only 5% Collective Protest action).

52 publishers, 11 languages

Framing Bias

Dominant frame is deal-as-achievement, focusing on tariff reduction percentages and executive action. Headlines emphasize deal completion ('Deal sealed', 'Trade deal done'), credit to leaders ('PM Modi thanks him', 'Trump announces'), and numerical outcomes ('tariffs cut to 18%'). Sample headlines show minimal critical or protest language.

Key Findings

• -Coverage is overwhelmingly English-language (91% of titles).
• -Entity focus is strongly bilateral (IN:164, US:144 mentions), with Russia (RU:24) as a minor third-party reference.
• -Top actors are almost exclusively executives (Us Executive:130, In Executive:84), with minimal corporate (Corporation:8) or population (In Population:7) representation.
• -Three competing narrative frames exist but receive minimal coverage (Label coverage 97% for dominant frame).

Blind Spots

• ?US domestic political opposition perspective
• ?Indian state-level or regional government views
• ?Perspectives from other major trade partners (e.g., EU, China) affected by the deal

Missing Perspectives

• ?What are the specific grievances of the protesters (only 13 titles on Collective Protest)?
• ?What sectors or groups in India/US stand to lose from the deal?
• ?How does the deal fit into broader US strategic competition with China?
• ?What were the negotiation concessions not mentioned in the triumphant announcements?

Follow the Gain

The current framing primarily benefits the US and Indian executives (Trump, Modi), presenting them as successful dealmakers. It also benefits the narrative of a strengthened bilateral strategic partnership, potentially marginalizing domestic opposition and protesters framed as 'villains'.